| Pharmaceutical Information |
| Drug Name |
Telbivudine |
| Drug ID |
BADD_D02145 |
| Description |
Telbivudine is a synthetic thymidine nucleoside analog with specific activity against the hepatitis B virus. Telbivudine is orally administered, with good tolerance, lack of toxicity and no dose-limiting side effects. |
| Indications and Usage |
For the treatment of chronic hepatitis B in adult and adolescent patients ≥16 years of age with evidence of viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease. |
| Marketing Status |
approved; investigational |
| ATC Code |
J05AF11 |
| DrugBank ID |
DB01265
|
| KEGG ID |
D06675
|
| MeSH ID |
D000077712
|
| PubChem ID |
159269
|
| TTD Drug ID |
D0CL9S
|
| NDC Product Code |
Not Available |
| UNII |
2OC4HKD3SF
|
| Synonyms |
Telbivudine | 1-(2-Deoxy-beta-L-erythropentafuranosyl)-5-methyl-2,4(1H,3H)-pyrimidinedione | beta-L-2'-Deoxythymidine | beta L 2' Deoxythymidine | Telbivudin | Tyzeka |
|
| Chemical Information |
| Molecular Formula |
C10H14N2O5 |
| CAS Registry Number |
3424-98-4 |
| SMILES |
CC1=CN(C(=O)NC1=O)C2CC(C(O2)CO)O |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
|
|
|
